Positive Long-Term VenoValve® First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum

– First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery – No venous ulcer recurrences, relapses of CVI, or safety issues – Improvements in average Reflux, disease manifestations (VCSS), and pain (VAS) endpoints continue to be encouraging